| Today's Top Story |  |  | | - FDA expands approval of Genentech's arthritis drug Actemra
The FDA approved Actemra, or tocilizumab, to treat adults with moderate to severe rheumatoid arthritis who have inadequate response to one or more disease-modifying antirheumatic drugs. The drug, by Roche Holding unit Genentech, is already approved for systemic juvenile idiopathic arthritis. Drug Store News (10/12)       | | Health Care & Policy | | | | - Sanofi will boost MS business with next-generation Lemtrada
Sanofi is looking to expand its multiple sclerosis business by developing a second-generation version of Lemtrada, or alemtuzumab, an investigational drug acquired after buying Genzyme last year. The new version is set to enter clinical development and might be evaluated for other immune diseases. Sanofi is on course to resubmit Lemtrada for FDA approval, said Michael Panzara, Genzyme's head of MS therapy. Bloomberg Businessweek (10/12) - Merck's odanacatib works against osteoporosis in Phase II study
Merck & Co.'s experimental drug odanacatib improved hip and spine bone mineral density in a midstage study involving 243 postmenopausal women previously treated with the drugmaker's osteoporosis treatment Fosamax, or alendronate. "Odanacatib may be a viable alternative for patients who need continued therapy and who want benefits beyond what they received from bisphosphonates," said Albert Leung, a senior research executive at Merck. Reuters (10/13) | Company & Financial News | | | | | Food & Agriculture | | | | | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - San Diego is a hub for advanced-biofuel startups
San Diego's blend of resources, technical expertise and supportive policies has turned it into a hub for advanced-biofuel startups such as Sapphire Energy and Cellana. "San Diego has developed as the Mecca of algae technology development, as well as a model community for the cleantech movement," according to David Schwartz, editor of an online algae-biofuels trade publication. "This is largely due to a remarkable convergence of ... resources and brain trust [that] has resulted in the development of pioneering companies," Schwartz said. Bloomberg Businessweek (10/11) | News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | I have loved the stars too fondly to be fearful of the night."
--Galileo Galilei,
Italian astronomer, philosopher and physicist  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, October 12, 2012
- Thursday, October 11, 2012
- Wednesday, October 10, 2012
- Tuesday, October 09, 2012
- Monday, October 08, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment